Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Vivos Therapeutics (VVOS) Accumulated Depreciation & Amortization (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 11.19% to $3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.0 million, a 11.19% increase, with the full-year FY2024 number at $2.9 million, up 22.87% from a year prior.
  • Accumulated Depreciation & Amortization was $3.0 million for Q3 2025 at Vivos Therapeutics, up from $2.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.0 million in Q3 2025 to a low of $874076.0 in Q1 2021.
  • A 5-year average of $1.9 million and a median of $1.7 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 55.18% in 2021, then grew 11.19% in 2025.
  • Vivos Therapeutics' Accumulated Depreciation & Amortization stood at $1.2 million in 2021, then surged by 41.03% to $1.8 million in 2022, then surged by 32.69% to $2.3 million in 2023, then increased by 22.87% to $2.9 million in 2024, then rose by 6.05% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Accumulated Depreciation & Amortization are $3.0 million (Q3 2025), $2.9 million (Q4 2024), and $2.7 million (Q3 2024).